# Cognito Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cognito-therapeutics

- Industry: Medical Devices & Equipment
- Headquarters: Cambridge, US
- Website: www.cognitotx.com
- Total disclosed funding: $178M
- Latest round: Series C (Mar 5, 2026)
- Investors on record: 9

## About

Based in the US, Cognito Therapeutics, Inc., a.k.a. Cognito Therapeutics, operates as a developer of a headset to treat neurodegenerative diseases and improve human cognitive performance. Based in Massachusetts, US, and founded in 2016 by co-founders Ed Boyden and Li-Huei Tsai, Cognito Therapeutics, Inc., a.k.a. Cognito Therapeutics operates as a developer of disease-modifying therapeutic interventions for neurodegenerative diseases and human cognitive performance. In March 2026, Cognito Therapeutics, Inc. raised USD 105 million in series C funding from Morningside, IAG Capital Partners, Starbloom Capital, Vintage Partners, Apollo Health Ventures and Benvolio Group. Cognito Therapeutics provides an investigational therapeutic platform that delivers non-invasive neuromodulation by using sensory stimulation to evoke gamma oscillations in the brain with personalized treatments, adjustable fit, and self-administered features. The company's platform treats a range of neurodegenerative diseases, including Alzheimer’s disease, and is personalized based on the brain’s responses. Cognito Therapeutics generates revenue by commercializing physician-prescribed, non-invasive neurostimulation devices for Alzheimer’s and neurodegenerative diseases, earning income through device sales, clinical partnerships, and future reimbursement-based distribution following regulatory approvals and market launch. The company plans to use the March 2026 funding to support pivotal study data readout, prepare for FDA submission, advance clinical development of Spectris, and ready the product for commercialization in Alzheimer’s disease.

## Funding rounds

- Series C, Mar 5, 2026, $105M — Apollo Health Ventures, Morningside, IAG Capital Partners, Benvolio Group, Starbloom Capital, New Vintage Partners
- Series B, Mar 22, 2023, $73M — WS Investments, Alzheimer's Drug Discovery Foundation, FoundersX Ventures, IAG Capital Partners, Starbloom Capital

## Investors

- WS Investments (https://capitalatlas.ai/funds/ws-investments) — Series B
- Alzheimer's Drug Discovery Foundation — Series B
- FoundersX Ventures (https://capitalatlas.ai/funds/foundersx-ventures) — Series B
- IAG Capital Partners (https://capitalatlas.ai/funds/iag-capital-partners) — Series B, Series C
- Starbloom Capital (https://capitalatlas.ai/funds/starbloom-capital) — Series B, Series C
- Apollo Health Ventures (https://capitalatlas.ai/funds/apollo-health-ventures) — Series C
- Morningside (https://capitalatlas.ai/funds/morningside) — Series C
- Benvolio Group (https://capitalatlas.ai/funds/benvolio-group) — Series C
- New Vintage Partners (https://capitalatlas.ai/funds/new-vintage-partners) — Series C